unknown
Stage
About
Espervita Therapeutics develops first-in-class acetyl-CoA metabolic enzyme inhibitors targeting metabolic diseases such as steatohepatitis, chronic kidney disease, and liver fibrosis, with a lead compound showing efficacy in preclinical models.
Explore Espervita's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.